Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

Phase 4

Recruiting

• Conditions: Acute Coronary Syndromes
• Interventions: Drug: Atorvastatin 40 mg; Drug: Rosuvastatin 20 mg/day

• Registration Number: NCT06765265
• Lead Sponsor: King Edward Medical University

Brief Summary

there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months

Detailed Description

this randomized clinical trial will include 152 patients of acute coronary syndrome with normal Vitamin D levels. they will be randomized to receive either Atorvastatin or Rosuvastatin. After 6 months of therapy, the impact on Vitamin D levels will be checked

Study Timeline

• Study First Submitted: 2025-01-03
• Study First Submitted QC: 2025-01-03
• Study Start: 2025-01-05
• Study First Posted: 2025-01-09
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-07
• Last Update Posted: 2025-03-11
• Primary Completion: 2026-01-01
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

Acute Coronary Syndrome

25 OH-Vitamin D levels between 30-70ng/ml

Exclusion Criteria

Hypercalcemia

hypocalcemia

pregnancy

lactation

hypersensitivity to statins

hypothyroidism

Deranged LFTs & RFTs

Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Atorvastatin	Atorvastatin 40 mg	Atorvatstain 40mg OD
Rosuvastatin	Rosuvastatin 20 mg/day	Rosuvastatin 20mg

Primary Outcome Measures

Name	Time	Method
Serum Vitamin D	24 weeks

Secondary Outcome Measures

Name	Time	Method
Lipid Profile	4 weeks & 24 weeks

Trial Locations

Locations (1)

King Edward Medical University; 🇵🇰 Lahore, Punjab, Pakistan